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Ariberto FassatiTwo independent papers show that IFITMs
proteins are incorporated into HIV-1 particles and
restrict infection at an early stage
Five members of the interferon inducible transmembrane
(IFITM) gene family are found in humans: IFITM1, 2, 3, 5
and 10. Typically, IFITMs 1, 2 and 3 are induced by both
type I and type II interferon [1,2] although they are also
constitutively expressed in cells of the upper airway and
visceral pleura. IFITM 5 is not interferon-inducible and is
involved in bone mineralization, and IFITM10 function is
unknown. IFITM1, 2 and 3 are likely to have arisen from
lineage and species-specific gene duplications. Indeed they
are highly similar and highly conserved genes throughout
evolution, with at least one member present in jawless fish
(lampreys). The rapid expansion of the IFITM gene family
during mammalian evolution was accompanied by positive
selection, suggesting a broad role as antivirals. Conversely,
IFITM5 and 10, which are not interferon-inducible, show
no sign of gene duplications and positive selection [3,4].
IFITMs, as the name suggests, are located at membranes;
IFITM1 is found mainly at the plasma membrane, IFITM2
and 3 are found mainly in intracellular compartments and
endosomal membranes, although stimulation with inter-
feron can change their distribution [5,6].
IFITMs have been shown to restrict influenza A virus
(IAV) infection, in vitro and in a Ifitm3-/- mouse model
[7-9]. IFITM3 restricts IAV infection more potently than
IFITM1 and 2, acting at the early stages of the viral replica-
tive cycle, most likely fusion [7]. Furthermore, Caucasian
and Han Chinese individuals bearing the synonymous sin-
gle nucleotide polymorphism (SNP) rs12252 in the IFITM3
gene were significantly more likely to suffer from severe
IAV infection and be hospitalized [8]. This SNP resulted in
a truncated IFITM3 protein that is found mainly at the cell
membrane instead of endosomal membranes [8]. IAV fusion
and release into the cytoplasm occurs in the late endosomal
compartment following acidification. Therefore it is likely
that IFITM3 needs to be in the right intracellular compart-
ment to exert its anti-IAV activity.Correspondence: a.fassati@ucl.ac.uk
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of different viruses, including West Nile and Dengue,
Vescicular stomatitis, Rabies, SARS coronavirus, Semliki
forest and several Bunyaviridae, with the exception of
Crimean-Congo haemorragic fever virus. IFITMs inhibit
virus infection by preventing efficient virus-cell fusion and
it is quite possible that several IFITMs with different intra-
cellular location have arisen to protect against viruses
using different entry pathways [6]. Interestingly, Hepatitis
C virus, murine leukaemia virus and Lassa virus are not
restricted by IFITMs proteins, which is quite puzzling
given that these viruses have overlapping entry pathways
with other viruses that are restricted [6].
Whether HIV-1 is restricted by IFITMs has remained
somewhat controversial. Early reports suggested that HIV-1
was not restricted, at least in HeLa-CD4 cells [7]. However
a later study showed that in CD4+ T cells, replication of
HIV-1 was indeed impaired [10]. In this study, IFITM 2 and
3 reduced infection at an early stage, presumably at entry,
whereas IFITM1 mainly reduced virus production [10].
Now two studies, one by Tartour et a. published in Retro-
virology and another by Compton et al. published in Cell
Host and Microbe, convincingly demonstrate that IFITMs
do indeed restrict HIV-1 infection. Remarkably, both stud-
ies report that up-regulation of IFITMs expression in target
cells is insufficient to cause a significant block of HIV-1
infection. Instead, IFITMs expression at both producer and
target cells was necessary for restriction. In any case,
expression of IFITMs in producer cells results in more
potent restriction than its expression in target cells, which
was unexpected and unprecedented.
Tartour et al. and Compton et al. report that IFITMs
were incorporated into HIV-1 particles, which cause their
infectivity to drop. Furthermore, Compton et al. show that
stimulation with interferon type I up-regulates IFITMs in
primary CD4+ T cells, which, as expected, results in re-
duced virus replication. In a complementary fashion, Tar-
tour et al. show that primary macrophages behaved in a
similar way and produced HIV-1 particles with lower
infectivity upon upregulation of IFITMs. In agreement
with previous reports, Compton et al. show that HIV-1 is
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Using nice imaging, the two studies demonstrate that,
upon stimulation with interferon, IFITMs co-localises
with sites of virus budding at the plasma membrane and
with sites of Env accumulation at intracellular sites.
Both studies agree that the presence of IFITMs at the
virus membrane impairs fusion, which is consistent with
studies on other viruses. In addition, Compton at al.
found that cell-to-cell virus transmission is also impaired
by IFITMs and that this reduction is due to less efficient
fusion at the virological synapse.
Several questions arise from these studies: why must
IFITMs be incorporated into HIV-1 particles to be
restrictive? Consensus has it that amphotropic MLV and
HIV-1 fuse at the cell membrane in a pH-independent
way, so why is HIV-1 susceptible and amphotropic MLV
not susceptible to IFITMs? How is HIV-1 fusion inhi-
bited? Furthermore, it will be interesting to examine the
effect of the IFITM3 SNP rs12252 on HIV-1 infection:
would aberrant localization of IFITM3 at the plasma mem-
brane make HIV-1 more or less susceptible to restriction?
The two studies by Crompton et al. and Tartour
et al. are important because they extend our knowledge
on interferon-regulated genes that impact on HIV-1
infection and also because they point to a potentially
new mechanism to explain IFITMs antiviral activity. It
will be important to investigate if IFITM3 SNPs found
in Han Chinese adversely affects progression to AIDS
and if HIV-1 evolves differently in individuals carrying
this SNP.
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